Membrane chromatography offers significant advantages over traditional column chromatography, including higher throughput, reduced processing times and enhanced scalability, making it an interesting tool in biologics production.
This study investigates the use of Protein A membrane chromatography for monoclonal antibody (mAb) purification in a contract research, development and manufacturing organization (CRDMO) setting involved in biologics development and manufacturing of first-in-human (FIH) molecules.
The expert speakers focus on the use of a mAb platform from resin-based to membrane Protein A chromatography, evaluating productivity, material cost and plant occupancy at 50, 500 and 2000 L scales. Results indicate this technology’s potential benefits for clinical development and improved operational flexibility.
Register for this webinar to understand how advanced technology can enhance throughput, reduce processing times and scales efficiently in a CRDMO setting for first-in-human molecule production.
